Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...
Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...
The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...
Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...
Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...
I mean, with all the development we've seen in multiple myeloma ... in rural areas who may not have access even to bispecific antibodies, which you can argue can be given without the need of ...
The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...
That's a great question, because quality of life is a very important concept that we need always to focus on, treating multiple myeloma ... like bispecific antibodies to prevent infections ...